- Visibility 104 Views
- Downloads 59 Downloads
- Permissions
- DOI 10.18231/pjms.v.15.i.2.337-340
-
CrossMark
- Citation
Evaluation of Acinetobacter baumannii antibiotic resistance from tertiary care hospital – Judging the silent storm
- Author Details:
-
Bhabhor Ullas H
-
Patel Alpa S
-
Mullan Summaiya A
Introduction: Over the closing decades, Acinetobacter baumannii has globally emerged as an enormously troublesome nosocomial pathogen. Its scientific importance has been in large part pushed through a fantastic cap potential to collect or upregulate numerous resistance determinants, making it one of the maximum a success multidrug-resistant (MDR) organisms threatening modern-day antibiotic therapy. On pinnacle of such captivating resistance acquisition, A. baumannii is endowed with more than one mechanisms of survival below a huge variety of environments, potentiating capability for health facility spread. The attributable mortalities in patients with A. baumannii healthcare-related infections, of which ventilator-related pneumonia and bloodstream infections are the maximum common, can variety from 5% in widespread health facility wards to 54% with inside the in depth care unit (ICU), with growing reviews of community-received A.baumanni infections. Mounting proof of extensively drug-resistant (XDR) and pandrug-resistant (PDR) isolates of A. baumannii is likewise gathering in different countries. The World Health Organization (WHO) has assigned A. baumannii as a vital precedence pathogen posing a wonderful risk to human health, and toward which new antibiotics are urgently needed.
Aim & Objective: To evaluate various sample types from which Acinetobacter is isolated and evaluate antibiotic resistance pattern of Acinetobacter baumanii.
Materials and Methods: This retrospective observational study has taken the data from January 2021 to June 2022. The data collection was done in the month of May 2023 followed by data analysis in June 2023 to July 2023. A total of 1058 Acinetobacter baumanii were isolated from January 2021 to June 2022 from various sample that come to microbiology department, which includes tissue, sputum, Blood, pus, swab, CSF, ET Tube, urine, drain, CVP/DLC tip and body fluids. The data was entered into Microsoft Excel (Windows 10), and analysis was performed using Microsoft Excel, including frequency distribution and percentage.
Results: Out of 8226 (27.1%) positive culture 1058 ( 12.8%) were Acinetobacter baumannii isolates from various samples. highest resistance was seen with Ceftazidime (91.2%), followed by Piperacillin (88.5%), Ciprofloxacin (86.9%), Meropenem (82.6%), Imipenem (81.9%), Gentamicin (76.9%), Ampicillin-Sulbactam (68.6%), Amikacin (64.4%) and Tetracycline (57.5%). While Polymyxin B and Colistin was 100% sensitive.
Conclusions: Guarded use of all antimicrobials needs to be done. As in our study also shows resistant to at least one antibiotic in three groups or more of the isolates.
References
- Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics. 2020;9(3):119.
- Vrancianu CO, Gheorghe I, Czobor IB, Chifiriuc MC. Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of acinetobacter baumannii. Microorganisms. 2020;8(6):935.
- Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.
- Levy-Blitchtein S, Roca I, Plasencia-Rebata S, Vicente-Taboada W, Velásquez-Pomar J, Muñoz L, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru article. Emerg Microbes Infect. 2018;7(1):119.
- Nasr P. Genetics, epidemiology, and clinical manifestations of multidrugresistant Acinetobacter baumannii. J Hosp Infect. 2020;104:4–11.
- Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: Evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98.
- Kyriakidis I, Palabougiouki M, Vasileiou E, Tragiannidis A, Stamou M, Moudiou T, et al. Candidemia complicating biliary atresia in an infant with hemoglobinopathy. Turk Pediatri Ars. 2019;54(2):129–
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.
- Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
- Pakharukova N., Tuittila M., Paavilainen S., Malmi H., Parilova O., Teneberg S., Knight S.D., Zavialov A.V. Structural basis for Acinetobacter baumannii biofilm formation. Proc Natl Acad Sci USA. 2018;115(21):5558–63.
- Yang CH, Su PW, Moi SH, Chuang LY. Biofilm formation in Acinetobacter baumannii: Genotype-phenotype correlation. Molecules. 2019;24(10):1849.
- Krzyściak P., Chmielarczyk A., Pobiega M., Romaniszyn D., Wójkowska-Mach J. Acinetobacter baumannii isolated from hospital-acquired infection: Biofilm production and drug susceptibility. APMIS. 2017;125(11):1017–26.
- Jia W, Li C, Zhang H, Li G, Liu X, Wei J. Prevalence of genes of OXA-23 carbapenemase and AdeABC efux pump associated with multidrug resistance of Acinetobacter baumannii isolates in the ICU of a compre- hensive hospital of northwestern China. Int J Environ Res Public Health. 2015;12(8):10079–92.
- Farsiani H, Mosavat A, Soleimanpour S, Nasab MN, Salimizand H, Jameh- dar SA, et al. Limited genetic diversity and extensive antimicrobial resist- ance in clinical isolates of Acinetobacter baumannii in north-east Iran. J Med Microbiol. 2015;64(7):767–73.
- Rynga D, Sharif M, Deb M. P henotypic and molecular characterization of clinical isolates of Acinetobacter baumannii isolated from Delhi, India. Ann Clin Microbiol Antimicrob. 2015;14(1):40.
- Noori M, Mohsenzadeh B, Bahramian A, Shahi F, Mirzaei H, Khoshnood S. Characterization and frequency of antibiotic resistance related to membrane porin and efux pump genes among Acinetobacter baumannii strains obtained from burn patients in Tehran, Iran. J Acute Dis. 2019;8(2):63.
- Rahbarnia L, Farajnia S, Khaneshi H, Farajnia H, Naghili B, Tanomand A. Detection of blaOXA -23 and blaNDM-1 carbapenemase among clinical isolates of A. baumannii in Tabriz, north-west of Iran. Gene Rep. 2019;18(4):100555.
- Cortez-Cordova J, Kumar A. Activity of the efux pump inhibitor phenylalanine-arginine β-naphthylamide against the AdeFGH pump of Acinetobacter baumannii. Int J Antimicrob Agents. 2011;37(5):420–4.
How to Cite This Article
Vancouver
H BU, S PA, A MS. Evaluation of Acinetobacter baumannii antibiotic resistance from tertiary care hospital – Judging the silent storm [Internet]. Panacea J Med Sci. 2025 [cited 2025 Oct 27];15(2):337-340. Available from: https://doi.org/10.18231/pjms.v.15.i.2.337-340
APA
H, B. U., S, P. A., A, M. S. (2025). Evaluation of Acinetobacter baumannii antibiotic resistance from tertiary care hospital – Judging the silent storm. Panacea J Med Sci, 15(2), 337-340. https://doi.org/10.18231/pjms.v.15.i.2.337-340
MLA
H, Bhabhor Ullas, S, Patel Alpa, A, Mullan Summaiya. "Evaluation of Acinetobacter baumannii antibiotic resistance from tertiary care hospital – Judging the silent storm." Panacea J Med Sci, vol. 15, no. 2, 2025, pp. 337-340. https://doi.org/10.18231/pjms.v.15.i.2.337-340
Chicago
H, B. U., S, P. A., A, M. S.. "Evaluation of Acinetobacter baumannii antibiotic resistance from tertiary care hospital – Judging the silent storm." Panacea J Med Sci 15, no. 2 (2025): 337-340. https://doi.org/10.18231/pjms.v.15.i.2.337-340